TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force
Executive Summary
The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.
You may also be interested in...
Quintiles' Stake In NitroMed Is First Co-Investment With Care Capital
Quintiles' stake in nitric oxide-based medicines company NitroMed represents one of two initial co-investments under a strategic alliance with venture capital firm Care Capital.
Quintiles' Stake In NitroMed Is First Co-Investment With Care Capital
Quintiles' stake in nitric oxide-based medicines company NitroMed represents one of two initial co-investments under a strategic alliance with venture capital firm Care Capital.
Quintiles To Invest $50-$100 Mil. In "Non-Traditional" Outsourcing Deals
Quintiles plans to invest $50 mil. to $100 mil. in risk-sharing and other "non-traditional" outsourcing deals over the next several years, CEO Dennis Gillings, PhD, told investors at the company's Investor Day Conference in New York City Nov. 30.